Dolutegravir improves physical health-related quality of life in adults with HTLV-1 infection: A randomized controlled trial.
Int J Infect DisJun 28, 2026 (epub)
Clinical ResearchInfectious Diseases
Liliane Lins-Kusterer, Iris Montaño-Castellón, Estela Luz et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of dolutegravir on health-related quality of life (HRQoL) in adults with HTLV-1 infection over 96 weeks. Participants receiving dolutegravir showed significant improvements in physical health compared to those receiving vitamin C, with an adjusted mean difference in Physical Component Summary scores of 3.92.
Key findings
- Dolutegravir improved Physical Component Summary scores by an adjusted mean difference of 3.92 compared to vitamin C.
- No significant difference was found in Mental Component Summary scores between the two groups.
- Improvements were noted in physical functioning and pain domains for the dolutegravir group.
Why it matters
The study highlights the potential of dolutegravir to enhance physical health-related quality of life in patients with HTLV-1, suggesting a need for further exploration of integrase inhibitors in this context.